MDS 2026 Congress (Seoul) Highlights

Hi all,
I recently attended the MDS Congress in Seoul and shared highlights at our DCOP meet-up. Here’s a short summary for anyone who missed it. :brain:
Big picture: Research is moving toward a continuous cycle: understand the disease at the genetic and molecular level, test targeted interventions, measure the response with biomarkers, and refine. The aspirational goal is precision medicine for PD.

Scientific highlights

  • Genes to therapy: The Fahn lecture on GCH-1 and the Marsden pedigree-based lecture showed how genetic findings point to mechanisms and treatment targets.
  • Targeted trials: Senescence-targeting work and a microglia/neuroinflammation trial (PXS-4728A) used PET as a biomarker to check whether the mechanism was actually engaged.
  • Refining existing therapy: A temporal interference stimulation trial (STN vs. GPi) and ARISE for motor fluctuations.
  • Patient stratification: Sessions on co-pathologies, aging and comorbidities, and early/prodromal PD focused on who we enroll and how we group patients.
  • Digital health and AI: Continuous monitoring in natural settings can pick up subtle motor changes, which helps early detection, phenotyping, and outcome assessment.
  • Genetic therapies: Gene replacement and gene editing look most promising in monogenic and pediatric disorders. Only one licensed DNA replacement treatment exists for movement disorders so far, and α-synuclein-lowering siRNA programs in PD are still early (Phase 1).
  • Inclusion: The Kenya prevalence study highlights populations still missing from genetic and trial data.

Industry updates

  • Lundbeck: Late-breaking Phase III MASCOT (amlenetug in MSA), a CSF α-synuclein assay to separate MSA from PD, and Phase Ib data for Lu AF28996 in motor complications.
  • Bial: Opicapone long-term safety, sublingual apomorphine for tremor, and the PEPP (patient endpoint preference) and TRACK-PD (treatment adherence) studies.

For discussion: Which of these themes (multimodal data integration, digital biomarkers, or stratification by co-pathology) do you see as most relevant to our data work? Would love to hear your thoughts and any highlights you caught from the congress and continue the discussion from the webinar earlier this week in this forum.

Thanks to everyone who joined the meet-up!

4 Likes